WO2014206279A1 - Lactic acid bacteria and preparation method and use of fermented grains or grain germ extracts - Google Patents
Lactic acid bacteria and preparation method and use of fermented grains or grain germ extracts Download PDFInfo
- Publication number
- WO2014206279A1 WO2014206279A1 PCT/CN2014/080665 CN2014080665W WO2014206279A1 WO 2014206279 A1 WO2014206279 A1 WO 2014206279A1 CN 2014080665 W CN2014080665 W CN 2014080665W WO 2014206279 A1 WO2014206279 A1 WO 2014206279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- acid bacteria
- grain
- fermented
- tumor
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 239000000284 extract Substances 0.000 title claims abstract description 53
- 241000894006 Bacteria Species 0.000 title claims abstract description 50
- 239000004310 lactic acid Substances 0.000 title claims abstract description 48
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 13
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 12
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 12
- 235000013339 cereals Nutrition 0.000 claims description 90
- 238000000855 fermentation Methods 0.000 claims description 31
- 230000004151 fermentation Effects 0.000 claims description 31
- 230000000259 anti-tumor effect Effects 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 19
- 239000000047 product Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 9
- 241000209140 Triticum Species 0.000 claims description 9
- 235000021307 Triticum Nutrition 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 239000007858 starting material Substances 0.000 claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000012071 phase Substances 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 4
- 235000012041 food component Nutrition 0.000 claims description 4
- 239000005417 food ingredient Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000001641 gel filtration chromatography Methods 0.000 claims description 4
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 4
- 229940073490 sodium glutamate Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 240000001929 Lactobacillus brevis Species 0.000 claims description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 235000021001 fermented dairy product Nutrition 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 235000012149 noodles Nutrition 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 235000013580 sausages Nutrition 0.000 claims description 2
- 235000020183 skimmed milk Nutrition 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 2
- 238000009461 vacuum packaging Methods 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims 6
- 240000005979 Hordeum vulgare Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000007602 hot air drying Methods 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 238000009630 liquid culture Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 39
- 230000005764 inhibitory process Effects 0.000 description 26
- 238000011580 nude mouse model Methods 0.000 description 25
- 241000699660 Mus musculus Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 17
- 206010009944 Colon cancer Diseases 0.000 description 14
- 208000029742 colonic neoplasm Diseases 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 9
- 229940028885 interleukin-4 Drugs 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 241000209219 Hordeum Species 0.000 description 7
- 235000021109 kimchi Nutrition 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- OLBNOBQOQZRLMP-UHFFFAOYSA-N 2,6-dimethoxy-p-benzoquinone Chemical compound COC1=CC(=O)C=C(OC)C1=O OLBNOBQOQZRLMP-UHFFFAOYSA-N 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 238000010876 biochemical test Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229940069780 barley extract Drugs 0.000 description 2
- 108700000707 bcl-2-Associated X Proteins 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000020083 shōchū Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 239000010205 Avemar Substances 0.000 description 1
- 101710130006 Beta-glucanase Proteins 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000718541 Tetragastris balsamifera Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003783 cell cycle assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- GYGVOUCJZPMINH-UHFFFAOYSA-N hydrogen peroxide sulfane Chemical compound S.OO GYGVOUCJZPMINH-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000021489 probiotic drink Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 150000003641 trioses Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/152—Cereal germ products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/121—Brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- the invention relates to the field of food biotechnology, and particularly relates to bio-transformation by fermentation of lactic acid bacteria by using cereal or grain germ (barley, wheat germ, etc.) as raw materials, thereby realizing the increase and enrichment of functional active components, and preparing to inhibit tumor cell proliferation. And a fermented extract of tumor growth, the inventive product can be used for the preparation of functional foods, food ingredients or pharmaceuticals. Background technique
- the number of people worldwide who die from malignant tumors is more than 7 million a year, and the number is still rising.
- the treatment of cancer mainly includes surgery, chemotherapy, radiotherapy and targeted therapy (immunotherapy, gene therapy, angiogenesis inhibitors and targeted therapy), and its side effects still bring a lot of pain to patients. Therefore, the development of natural safe, non-toxic and anti-tumor active substances and their functional foods or drugs are the cravings of cancer patients.
- Natural grain or grain germ is rich in a variety of functional substances, such as proteins, flavonoids, polyphenols, etc., with certain antioxidant and anti-tumor properties.
- functional substances such as proteins, flavonoids, polyphenols, etc.
- antioxidant and anti-tumor properties due to the low content or activity of functional ingredients, it is difficult to achieve significant effects. Therefore, the use of biotransformation technology to improve the nutritional quality and functional properties of grain or grain germ has attracted the attention of researchers at home and abroad, and has achieved certain results.
- the Hungarian patent discloses a method for detecting 2,6-dimethoxy-p-benzoquinone as an active substance and an antitumor product thereof (A V emar).
- the method comprises the steps of: pulverizing the wheat germ, fermenting with commercial baker's yeast, freeze-drying or spray-drying the supernatant, and adding the dry powder to a certain concentration of the aqueous solution to be added to the tumor cell, thereby inhibiting metabolism and metastasis of the tumor cell;
- the 2,6-dimethoxy-p-benzoquinone was extracted with chloroform or ethanol as a marker, and was quantified by HPLC, but the other components of the extract were not analyzed.
- the US patent (2010/135580A2) is similar to the Hungarian patent, except that it uses ethanol extraction and obtains the polypeptide from Avemar by molecular sieves and electrophoresis, with a relative molecular mass between 5 and 100 KD, and through cells and animals. Model tests have demonstrated that this range of polypeptides inhibits the growth of tumor cells.
- Japanese Patent (200510069392.8) discloses a preparation method of an antitumor preparation.
- the method comprises mixing wheat germ, soybean germ and rice germ in a certain ratio, heating the mixture with 110 ° C hot steam, and heating the steam heating product at 30 ° C for 48 h with a koji (Aspergillus oryzae).
- the obtained fermentation extract has an antitumor effect with an inhibition rate of 5% to 15%, and the patent does not analyze the antitumor component in the fermentation extract.
- Lactic acid bacterium is safe, non-toxic, non-pathogenic, and has unique probiotic properties. It is a globally recognized "GRAS" ( generally regarded as safe) grade food microorganism, commonly used in sour milk products, kimchi, Fermented meat products, probiotic drinks and other fermented foods.
- GRAS globally recognized “GRAS” ( generally regarded as safe) grade food microorganism, commonly used in sour milk products, kimchi, Fermented meat products, probiotic drinks and other fermented foods.
- GRAS globally recognized as safe
- the invention selects excellent starting strains from self-separated lactic acid bacteria or commercial lactic acid bacteria, optimizes fermentation conditions, establishes a fermentation process with high yield of fermentation extract and strong anti-tumor activity, and uses the extract to carry out various human tumor cells and Its tumor-bearing animal test confirmed that its extract has significant inhibition of tumor cell proliferation.
- the invention firstly provides a lactic acid bacteria which is derived from natural fermented kimchi by screening, separation, enrichment and physical and chemical analysis, and then obtains excellent lactic acid bacteria by using grain or grain germ (barley, wheat germ, etc.) as raw materials.
- the direct-injection fermentation of the lactic acid bacteria obtains a fermentation extract having an activity of inhibiting tumor cell proliferation, and the extract is separated, purified and analyzed.
- MTT apoptosis and cell cycle method were used to study the anti-tumor function of its components in vitro; the antitumor activity of the extract was studied by using a tumor-bearing nude mouse model (human tumor cells); comprehensive evaluation of the fermentation extract of the present invention Anti-tumor function and explore its action pathway.
- Lactobacillus Dy-1 its proposed taxonomic name is Lactobacillus plantarum; the strain was sent to the Chinese Academy of Sciences for microbiology research on April 18, 2012 at No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, China. The deposit of the General Microbiology Center of the China Microbial Culture Collection Management Committee is CGMCC No.6016.
- the deposit number is CGMCC. No.6016; or choose Commercially available lactic acid bacteria such as one or more of Lactobacillus plantarum, Lactobacillus brevis, Lactobacillus acidophilus, and Lactobacillus case are selected.
- 1:6 ⁇ 1: 15 ratio preferably 1:7 ratio is added to distilled water, then lactic acid bacteria are added to the grain or grain germ, wherein the lactic acid bacteria account for 2 ⁇ 8% of the quality of fresh grain or grain germ powder, and the mixture is even;
- the bottle is sealed with gauze, placed in a constant temperature incubator, and fermented at 20 ⁇ 40 °C for 12 ⁇ 72h, wherein the fermentation temperature is preferably 30 ⁇ 35 °C, after fermentation for 24 ⁇ 48 h, the fermentation is 3000 ⁇ 12000g at room temperature.
- the lactic acid bacteria selected in the step (1) are activated by MRS liquid medium and cultured at a high density, and a protective agent (20% skim milk, 10% trehalose, 14% sodium glutamate, 6% sorbitol, and the like) are added. 6%Vc, or 22% inulin, 12% sodium glutamate, 5% sorbitol), then prepare the directly used lactic acid bacteria Dy-1 starter by vacuum freeze-drying, and seal it in a sterile vacuum packaging bag. Deposit for use.
- the grain described therein is preferably barley or glutinous rice or buckwheat.
- the grain germ described therein is preferably a wheat germ or a soybean germ.
- lactic acid bacteria to ferment cereals or grain germ extracts can be used to prepare anti-tumor functional foods or drug development.
- the preparation method of the food having anti-tumor function is carried out according to the following steps:
- the fermented cereal or cereal germ extract of the present invention is added to fermented dairy products and other acidic beverages in a certain ratio to prepare a functional beverage; it can also be added as food ingredients to foods such as bread, noodles, sausages and biscuits.
- the isolated and purified active fraction is directly used as a functional food or for anti-tumor drug development.
- the fermented cereal or cereal germ extract of the present invention there is no particular weight requirement for adding the fermented cereal or cereal germ extract of the present invention to a foodstuff, and the amount is usually from 1% to 15%, preferably from 4% to 10% by mass; the extract may also be directly or After separation and purification, it is directly used as food or medicine.
- the present invention utilizes autonomously isolated lactic acid bacteria to ferment cereal or grain germ to prepare a fermentation extract having anti-tumor function Take the object, with independent intellectual property rights.
- the invention adopts simple pretreatment (non-high temperature heating) on grain or grain germ, has low production cost, adopts direct-injection fermentation, is convenient, fast, safe and stable, and is convenient for quality control.
- the invention uses cereal or grain germ as raw material, has wide source and large reserves, and bio-transforms it to significantly improve the biological function and nutritional quality of grain or grain germ, and guides enterprises to apply modern biotechnology to produce healthy and high. Valued products.
- the present invention studies the anti-tumor activity active ingredients in the extract, and clarifies that the protein or polypeptide with a relative molecular mass below 40KD has significant anti-tumor effect, indicating that the moderate degradation of protein macromolecules during the fermentation of lactic acid bacteria is resistant.
- An important pathway for tumor activity and also provides a theoretical basis for the development of isolated foods or drugs.
- Figure 7 Inhibition of HT-29 cell proliferation by crude extract of crude protein and crude polyphenol extraction in FBE
- the collected kimchi samples were appropriately diluted by gradient and applied to the MRS double-layer plate method.
- the cells were cultured at 30 ° C for 36 h in an incubator. After the colonies grew, observe the growth of the plates and select the colonies in the plates. Appropriate (30 ⁇ 300) and calcium lysate are obvious for easy picking of colonies, record colony characteristics, select colonies, and pick colonies.
- the isolated strain was subjected to multiple scribing or coating separation to obtain a pure strain.
- the impure bacteria are again enriched and separated, the method is the same as above.
- the acid-producing ability of the obtained strains was compared by the acid-producing gas-producing test to obtain a strain with high acid yield; and the potential facultative anaerobic lactic acid bacteria were obtained by observing the strains which simultaneously produced acid and gas.
- the PCR product was purified and sequenced by Shanghai Biotech. The sequence is as follows:
- the 16S rRNA gene sequence of Dy-1 is only 3 bases different from the 16S rRN A gene sequence of Lactobacillus plantar um strain L3, and its similarity is more than 99%, which should belong to the same species. That is Lactobacillus plantarum.
- the strain was deposited on April 18, 2012 at the General Microbiology Center of the China Microbial Culture Collection Management Committee of the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Beichen West Road, Chaoyang District, Beijing, China.
- the deposit number is CGMCC No. 6016, its suggested classification name is Lactobacillus plantarum, Lactobacillus plantar called it lactic acid bacteria Dy-1
- the fermented cereal or cereal germ extract of the present invention is added to human HT-29 colon cancer cells at a concentration of 0.125 4 mg/mL, and cultured for a period of time (for example, 48 hours), and the anti-tumor effect is observed and evaluated. .
- the method is as follows -
- the number of living cells of the tumor can be reduced to 50% or less, and the number of living cells can be optimally reduced to 10% or less; Up to 50% or more, up to 90% or more.
- In vivo anti-tumor function The abdominal cancer of 46-week-old BALB/c nude mice was subcutaneously inoculated into human colon cancer HT-29 cells (inoculation amount: 1 10 6 2 10 7 cells/nude mice), and nude mice were visually observed after 2 15 days. At the inoculation site, the tumor was started and the stomach was started. The tumor-bearing nude mice were randomly divided into 5 groups, namely, the negative control group, the 5-FU positive control group, the high dose group, the low dose group, and the high dose group +5-FU group.
- wheat germ pulverized fresh wheat germ
- a 500mL Erlenmeyer flask add 100ml of distilled water to it, add 0.4g of lactic acid bacteria Dy-1 starter, mix evenly;
- the gauze was sealed and placed in a constant temperature incubator for 24 hours at 30 ° C. After centrifugation at 6500 g / min for 20 min, the supernatant was collected and lyophilized.
- Example 1 The filtrate in Example 1 was also added to SGC-7901 gastric cancer cells at 0.125 mg/mL, 0.25 mg/ml, 0.5 mg/mK 1.0 mg/mK 2.0 mg/mK 4.0 mg/ml, respectively.
- the inhibition rate of LFWGE on gastric cancer SGC-7901 cells was determined by MTT assay. The results showed that the concentration of extract was positively correlated with the inhibition rate of tumor cell proliferation, and the maximum inhibition rate reached 89.6%.
- the lmg/ml LFWGE was added to the SGC-7901 gastric cancer cells, and the cells were cultured for 48 hours, and the cells were collected, and the apoptosis of the cells was detected by flow cytometry. Early apoptosis was 48.5% and late apoptosis was 22.4%. LFWGE of 0.2 mg/ml, 0.4 mg/ml, and 0.8 mg/ml was added to gastric cancer cells, and the cells were cultured for 48 hours, and the cells were collected, and the cell cycle was detected by flow cytometry. The results showed that with the increase of concentration, the phase 1 was also prolonged, and the S phase was shortened, indicating that LFWGE can effectively block the phase 1 of cells.
- pulverized fresh barley 100 g was mixed with 1 L of distilled water and 4 g of lactic acid bacteria Dy-1 starter, and the mixture was fermented at 250 rpm for 24 h at 30 °C.
- the obtained fermentation product was centrifuged at 5000 g for 15 min, and the supernatant was collected and freeze-dried to obtain a fermented barley extract (FBE) lyophilized powder.
- the FBE was dissolved, and the protein was precipitated with 90% saturation of (NH 4 ) 2 S0 4 , centrifuged at 6000 g/min for 15 min, and the precipitate was dissolved in distilled water and dialyzed 3 times with a dialysis bag having a molecular weight of 8000-14000 Da.
- the LFWGE prepared above was dissolved in physiological saline to prepare an aqueous solution having a concentration of 0.2 g/ml and 0.1 g/ml, and was treated by a sterile membrane for use.
- Human HT-29 colon cancer cells were inoculated subcutaneously into 4-6 weeks old BALB/c nude mice, and 2 days later, 2g/kg/d, lg/kg/d, 2g/kg/d+5-FU (25 mg) /kg/d, ip, 7 days)
- the dose of LFWGE was administered to the tumor-bearing nude mice for 30 days of continuous gavage, and the same dose of saline group and intraperitoneal injection of 5-FU group (25 mg/kg/).
- TNF-a tumor necrosis factor
- IFN- ⁇ interferon
- IL-4 interleukin-4
- the FBE prepared above was dissolved in physiological saline to a concentration of 0.2 g/ml and 0.1 g/ml, and was treated by a sterile membrane for use.
- Human HT-29 colon cancer cells were inoculated subcutaneously into 4-6 week old BALB/c nude mice, and 2 days later, 2g/kg/d, lg/kg/d, 2g/kg/d+5-FU ( 25 mg/kg/d, ip, 7 days)
- the dose of FBE was administered to the tumor-bearing nude mice for 30 days, and the same dose of saline group and intraperitoneal injection of 5-FU group (25 mg/).
- SOD superoxide dismutase
- GSH-PX glutathione-peroxidase
- MDA malondialdehyde
- interferon IFN- ⁇
- interleukin-4 Fig. 21
- tumor necrosis factor TNF- ⁇
- Fig. 22 The concentration of interferon (IFN- ⁇ ) (Fig. 20), interleukin-4 (Fig. 21) and tumor necrosis factor (TNF- ⁇ ) (Fig. 22) in the serum of tumor-bearing nude mice was determined by enzyme-linked immunosorbent assay kit. show, FBE simultaneously can be increased IFN- Y, the content of interleukin-4 and TNF- ⁇ in.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed are a lactic acid bacteria, Lactobacillus plantarum, CGMCC No. 6016; the preparation method of fermented grains or grain germ extracts using the Lactobacillus plantarum; and the use of the Lactobacillus plantarum in fermented grains or grain germ extracts.
Description
乳酸菌及发酵谷物或谷物胚芽提取物的制备方法与用途 Preparation method and use of lactic acid bacteria and fermented cereal or cereal germ extract
技术领域 Technical field
本发明涉及食品生物技术领域, 特指以谷物或谷物胚芽 (大麦、 小麦胚芽等) 为原料, 通过乳酸菌发酵发生的生物转化, 实现功能活性组分的增加与富集, 制备具有抑制肿瘤细胞 增殖和肿瘤生长的发酵提取物, 该发明产品可用于功能性食品、 食品配料或药物的制备。 背景技术 The invention relates to the field of food biotechnology, and particularly relates to bio-transformation by fermentation of lactic acid bacteria by using cereal or grain germ (barley, wheat germ, etc.) as raw materials, thereby realizing the increase and enrichment of functional active components, and preparing to inhibit tumor cell proliferation. And a fermented extract of tumor growth, the inventive product can be used for the preparation of functional foods, food ingredients or pharmaceuticals. Background technique
世界卫生组织指出, 目前全球因恶性肿瘤导致死亡的人数每年达 700多万, 且数量仍在 不断攀升。 而对于癌症的治疗主要有手术、 化疗、 放疗及靶向疗法 (免疫疗法、 基因疗法、 血管生成抑制剂及定向疗法) 等方式, 其副作用仍会给患者带来许多痛苦。 因此, 开发天然 安全、 无毒副作用的抗肿瘤活性物质及其功能食品或药物是癌症患者的渴求。 According to the World Health Organization, the number of people worldwide who die from malignant tumors is more than 7 million a year, and the number is still rising. The treatment of cancer mainly includes surgery, chemotherapy, radiotherapy and targeted therapy (immunotherapy, gene therapy, angiogenesis inhibitors and targeted therapy), and its side effects still bring a lot of pain to patients. Therefore, the development of natural safe, non-toxic and anti-tumor active substances and their functional foods or drugs are the cravings of cancer patients.
天然谷物或谷物胚芽中富含多种功能性物质, 如蛋白质、 黄酮类、 多酚类等, 具有一定 的抗氧化、 抗肿瘤等特性。 但是由于其中功能成分含量或活性较低, 难以达到明显的效果。 因此, 采用生物转化技术提高以谷物或谷物胚芽的营养品质和功能特性, 引起国内外研究者 的关注, 并取得了一定的成果。 Natural grain or grain germ is rich in a variety of functional substances, such as proteins, flavonoids, polyphenols, etc., with certain antioxidant and anti-tumor properties. However, due to the low content or activity of functional ingredients, it is difficult to achieve significant effects. Therefore, the use of biotransformation technology to improve the nutritional quality and functional properties of grain or grain germ has attracted the attention of researchers at home and abroad, and has achieved certain results.
匈牙利专利(99/08694)公开了一种以 2,6-二甲氧基对苯醌为活性物质的检测方法及其抗 肿瘤产品(AVemar)。 该方法是将麦胚粉碎, 用商用面包酵母发酵, 将上清液进行冷冻干燥或 喷雾干燥, 将其干燥粉配制成一定浓度的水溶液加入到肿瘤细胞中, 能够抑制肿瘤细胞的代 谢和转移; 以氯仿或乙醇提取其中的 2,6-二甲氧基对苯醌为标志物, 采用 HPLC进行定量, 但未对提取物的其它成分进行分析。 美国专利(2010/135580A2)与匈牙利专利相似, 其不同 之处是采用乙醇提取并通过分子筛和电泳等方法从 Avemar 中获得多肽, 其相对分子质量在 5〜100 KD之间, 并通过细胞和动物模型试验证明该范围的多肽具有抑制肿瘤细胞的生长。 The Hungarian patent (99/08694) discloses a method for detecting 2,6-dimethoxy-p-benzoquinone as an active substance and an antitumor product thereof (A V emar). The method comprises the steps of: pulverizing the wheat germ, fermenting with commercial baker's yeast, freeze-drying or spray-drying the supernatant, and adding the dry powder to a certain concentration of the aqueous solution to be added to the tumor cell, thereby inhibiting metabolism and metastasis of the tumor cell; The 2,6-dimethoxy-p-benzoquinone was extracted with chloroform or ethanol as a marker, and was quantified by HPLC, but the other components of the extract were not analyzed. The US patent (2010/135580A2) is similar to the Hungarian patent, except that it uses ethanol extraction and obtains the polypeptide from Avemar by molecular sieves and electrophoresis, with a relative molecular mass between 5 and 100 KD, and through cells and animals. Model tests have demonstrated that this range of polypeptides inhibits the growth of tumor cells.
日本专利 (200510069392.8 ) 公开了一种抗肿瘤制剂的制备方法。 该方法是将小麦胚芽、 大豆胚芽及米胚芽等以一定的比例混合, 将混合物用 110°C热蒸汽加热, 并将蒸汽加热产物 在 30°C下用曲类 (小麦曲霉) 等发酵 48h, 所得的发酵提取物具有抗肿瘤效果, 其抑制率在 5%〜15%, 该专利未对发酵提取物中的抗肿瘤成分进行分析。 Japanese Patent (200510069392.8) discloses a preparation method of an antitumor preparation. The method comprises mixing wheat germ, soybean germ and rice germ in a certain ratio, heating the mixture with 110 ° C hot steam, and heating the steam heating product at 30 ° C for 48 h with a koji (Aspergillus oryzae). The obtained fermentation extract has an antitumor effect with an inhibition rate of 5% to 15%, and the patent does not analyze the antitumor component in the fermentation extract.
日本崇城大学 Kouta Funamoto, et al.在 2008年研究得出大麦烧酒的蒸馏残余物具有抗肿 瘤和免疫活性, 在体外能显著抑制人肺癌细胞的生长, 诱导肿瘤细胞凋亡, 在体内诱导能正 常老鼠血清干扰素 (IFN-γ) 的产生, 增加自然杀伤细胞 (NK) 的数量, 且通过尾静脉注射, 无急性毒性。 Masa iro Ohgidani, et al.在 2012年研究得出 SCID鼠注射 HepG2肝癌细胞后, 每天口服大麦烧酒的蒸馏残余物 2250 mg/kg体重, 连续 21天, 能显著减少肿瘤细胞, 诱导 肿瘤细胞凋亡, 延长 SCID鼠的寿命, 且未见副作用。
¥ 利和文献报道关于发酵产物的抗肿瘤研究, 主要 , 且其 对肿瘤的抑制效果尚未达到令人满意的程度。 Kouta Funamoto, et al. of Chongcheng University in Japan found that the distillation residue of barley shochu has anti-tumor and immune activity in 2008, which can significantly inhibit the growth of human lung cancer cells, induce tumor cell apoptosis, and induce energy in vivo. The production of serum interferon (IFN-γ) in normal mice increases the number of natural killer cells (NK) and is injected through the tail vein without acute toxicity. Masa iro Ohgidani, et al. in 2012, after the injection of HepG2 hepatoma cells into SCID mice, the daily distillation of barley shochu distillation residue 2250 mg / kg body weight for 21 consecutive days, can significantly reduce tumor cells, induce tumor cell apoptosis , prolong the life of SCID mice, and no side effects. ¥ and the literature report on anti-tumor research on fermentation products, mainly, and its inhibitory effect on tumors has not yet reached a satisfactory level.
乳酸菌 (lactic acid bacterium, LAB ) 安全无毒、 无致病性, 并具有独特的益生特性, 是全球公认的 " GRAS " ( generally regarded as safe) 等级食品微生物, 普遍应用于酸乳制品、 泡菜、 发酵肉制品、 益生饮料等发酵食品中。 但是, 关于其乳酸菌发酵产物抗肿瘤特性的研 究及产品开发尚未见有专利或其他文献报道。 基于此, 筛选能发酵谷物及谷物胚芽并获得具 有高生物活性产物的乳酸菌, 并确证其发酵产物的抗肿瘤功能, 从而制备出高效抗肿瘤功能 食品、 食品配料或药物, 是一个具有广阔的开发前景的研究领域。 Lactic acid bacterium (LAB) is safe, non-toxic, non-pathogenic, and has unique probiotic properties. It is a globally recognized "GRAS" ( generally regarded as safe) grade food microorganism, commonly used in sour milk products, kimchi, Fermented meat products, probiotic drinks and other fermented foods. However, research and product development on the anti-tumor properties of lactic acid bacteria fermentation products have not been reported in patents or other literature. Based on this, screening lactic acid bacteria capable of fermenting grain and grain germ and obtaining high bioactive products, and confirming the anti-tumor function of the fermentation product, thereby preparing a highly effective anti-tumor function food, food ingredient or medicine, is a broad development. The field of research for the future.
本发明从自行分离的乳酸菌或商用乳酸菌中筛选出优良的出发菌株, 优化发酵条件, 建 立发酵提取物产量高且抗肿瘤活性强的发酵工艺, 并采用该提取物进行多种人源肿瘤细胞及 其荷瘤动物试验, 确证其提取物具有显著的抑制肿瘤细胞增殖功能。 The invention selects excellent starting strains from self-separated lactic acid bacteria or commercial lactic acid bacteria, optimizes fermentation conditions, establishes a fermentation process with high yield of fermentation extract and strong anti-tumor activity, and uses the extract to carry out various human tumor cells and Its tumor-bearing animal test confirmed that its extract has significant inhibition of tumor cell proliferation.
发明内容 Summary of the invention
本发明首先提供的是源自自然发酵泡菜, 通过筛选、 分离、 富集以及理化分析等, 从中 获得一株性能优良的乳酸菌; 再以谷物或谷物胚芽 (大麦、 小麦胚芽等) 为原料, 通过该乳 酸菌的直投式发酵, 从中获得具有抑制肿瘤细胞增殖活性的发酵提取物, 并对该提取物进行 分离纯化与分析。 The invention firstly provides a lactic acid bacteria which is derived from natural fermented kimchi by screening, separation, enrichment and physical and chemical analysis, and then obtains excellent lactic acid bacteria by using grain or grain germ (barley, wheat germ, etc.) as raw materials. The direct-injection fermentation of the lactic acid bacteria obtains a fermentation extract having an activity of inhibiting tumor cell proliferation, and the extract is separated, purified and analyzed.
采用 MTT、细胞凋亡和细胞周期法研究其组分的体外抗肿瘤功能;采用荷瘤裸鼠模型(人 源肿瘤细胞) 研究该提取物的体内抗肿瘤活性; 综合评价本发明发酵提取物的抗肿瘤功能并 探索其作用途径。 MTT, apoptosis and cell cycle method were used to study the anti-tumor function of its components in vitro; the antitumor activity of the extract was studied by using a tumor-bearing nude mouse model (human tumor cells); comprehensive evaluation of the fermentation extract of the present invention Anti-tumor function and explore its action pathway.
本发明通过以下技术方案实现: The invention is achieved by the following technical solutions:
1、乳酸菌 Dy- 1,其建议的分类名称为植物乳杆菌, Lactobacillus plantarum;该菌株于 2012 年 4月 18日送交位于中国北京市朝阳区北辰西路 1号院 3号的中国科学院微生物研究所的中 国微生物菌种保藏管理委员会普通微生物中心保藏, 保藏编号为 CGMCC No.6016。 1. Lactobacillus Dy-1, its proposed taxonomic name is Lactobacillus plantarum; the strain was sent to the Chinese Academy of Sciences for microbiology research on April 18, 2012 at No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, China. The deposit of the General Microbiology Center of the China Microbial Culture Collection Management Committee is CGMCC No.6016.
2、 乳酸菌发酵谷物或谷物胚芽提取物的制备方法 2. Preparation method of lactic acid bacteria fermented grain or cereal germ extract
( 1)菌种的筛选与制备: 将泡菜样品分别进行适当的梯度稀释, 涂布于 MRS双层平板 上,恒温箱中于 30°C培养 36h,待菌落长出来后观察其生长情况,选择菌落合适(30~300个)、 溶钙圈明显并便于挑取菌落的平板, 记录菌落特征, 选择和挑取菌落。 从泡菜中筛选出 1 株 乳酸菌鉴定其功能特性, 其建议的分类名
plontorum ; 该菌株于 2012年 4月 18日送交位于中国北京市朝阳区北辰西路 1号院 3号的中国科学院微生物研究所 的中国微生物菌种保藏管理委员会普通微生物中心保藏, 保藏编号为 CGMCC No.6016; 或选
择商用优良乳酸菌,如植物乳杆菌(Lactobacillus plantarum)、短乳杆菌(Lactobacillus brevis)、 嗜酸乳杆菌 (Lactobacillus acidophilus )、 干酪乳杆菌 (Lactobacillus case) 中的一种或几种。 (1) Screening and preparation of strains: The kimchi samples were separately diluted by appropriate gradients, coated on MRS double-layer plates, and cultured in an incubator at 30 ° C for 36 h. After the colonies grew, observe the growth and select The colonies are suitable (30~300), the plate is obviously dissolved and the colony is easy to pick up, the colony characteristics are recorded, and the colonies are selected and picked. Screening of a strain of lactic acid bacteria from kimchi to identify its functional properties, its suggested classification name Plontorum ; The strain was deposited on April 18, 2012 at the General Microbiology Center of the China Microbial Culture Collection Management Committee of the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Beichen West Road, Chaoyang District, Beijing, China. The deposit number is CGMCC. No.6016; or choose Commercially available lactic acid bacteria such as one or more of Lactobacillus plantarum, Lactobacillus brevis, Lactobacillus acidophilus, and Lactobacillus case are selected.
(2)乳酸菌发酵谷物或谷物胚芽及其发酵提取物的制备:称取筛分除杂后的谷物或谷物 胚芽, 粉碎过 30〜140目筛, 置于锥形瓶中, 按照质量与体积比 1:6~1: 15比例, 优选 1:7的 比例加入蒸馏水, 再加入乳酸菌到谷物或谷物胚芽中, 其中乳酸菌占新鲜谷物或谷物胚芽粉 的质量为 2~8%, 混合均匀; 将锥形瓶用纱布封口, 置于恒温培养箱中, 在 20〜40°C下发酵 12〜72h,其中优选发酵温度 30〜35°C,发酵 24〜48 h后,发酵物在室温下 3000〜12000g/min 离心 10〜40min, 其中优选 5000〜6500g/min离心 20〜30min; 收集上清液, 并将其进行热风 干燥、 喷雾干燥或冷冻干燥, 优选冷冻干燥, 从而获得发酵谷物或谷物胚芽发酵提取物。 (2) Preparation of lactic acid bacteria fermented grain or grain germ and its fermented extract: Weigh the grain or grain germ after sieving and removing, smash it through a 30-140 mesh sieve, and place it in a conical flask according to the mass to volume ratio. 1:6~1: 15 ratio, preferably 1:7 ratio is added to distilled water, then lactic acid bacteria are added to the grain or grain germ, wherein the lactic acid bacteria account for 2~8% of the quality of fresh grain or grain germ powder, and the mixture is even; The bottle is sealed with gauze, placed in a constant temperature incubator, and fermented at 20~40 °C for 12~72h, wherein the fermentation temperature is preferably 30~35 °C, after fermentation for 24~48 h, the fermentation is 3000~12000g at room temperature. /min Centrifuge for 10~40min, preferably 5,000~6500g/min for 20~30min; collect the supernatant and heat dry, spray dry or freeze dry, preferably freeze-dry, to obtain fermented grain or grain germ fermentation Things.
(3)乳酸菌发酵谷物或谷物胚芽提取物的分离纯化: 采用硫酸铵沉淀、 高效液相(流动 相是甲醇与水的比例按照 20%〜15%, 流速为 lm!Jmin, 柱温为 25°C, 检测波长为 288nm。)、 凝胶过滤层析 (SephadexG-50禾 P SurpedexS-200)、 SDS-PAGE ( 5%的浓缩胶, 10%〜 12%的 分离胶) 对发酵谷物或谷物胚芽提取物进行分离纯化, 即可得到乳酸菌发酵谷物或谷物胚芽 提取物中的蛋白或多肽。 (3) Separation and purification of lactic acid bacteria fermented grain or grain germ extract: using ammonium sulfate precipitation, high-performance liquid phase (mobile phase is methanol to water ratio of 20%~15%, flow rate is lm! Jmin, column temperature is 25°) C, detection wavelength is 288 nm.), gel filtration chromatography (Sephadex G-50 and P Surpedex S-200), SDS-PAGE (5% concentrated gel, 10% ~ 12% separation gel) on fermented grain or grain germ The extract is isolated and purified to obtain a protein or polypeptide in the lactic acid bacteria fermented cereal or cereal germ extract.
其中步骤 (1 ) 中选用的乳酸菌采用 MRS液体培养基活化和高密度培养后, 添加保护剂 (以质量比计 20%脱脂乳、 10%海藻糖、 14%谷氨酸钠、 6%山梨醇和 6%Vc, 或者 22%菊粉、 12%谷氨酸钠、 5%山梨醇) 后采用真空冷冻干燥法制备可直接使用的乳酸菌 Dy-1发酵剂, 分 装于无菌真空包装袋中密封保藏待用。 The lactic acid bacteria selected in the step (1) are activated by MRS liquid medium and cultured at a high density, and a protective agent (20% skim milk, 10% trehalose, 14% sodium glutamate, 6% sorbitol, and the like) are added. 6%Vc, or 22% inulin, 12% sodium glutamate, 5% sorbitol), then prepare the directly used lactic acid bacteria Dy-1 starter by vacuum freeze-drying, and seal it in a sterile vacuum packaging bag. Deposit for use.
其中所述的谷物优选大麦或者薏米、 荞麦。 其中所述的谷物胚芽优选小麦胚芽或者大豆 胚芽。 The grain described therein is preferably barley or glutinous rice or buckwheat. The grain germ described therein is preferably a wheat germ or a soybean germ.
乳酸菌发酵谷物或谷物胚芽提取物的用途, 可以用于制备抗肿瘤的功能性食品或药物开 发。 The use of lactic acid bacteria to ferment cereals or grain germ extracts can be used to prepare anti-tumor functional foods or drug development.
具有抗肿瘤功能食品的制备方法, 按照下述步骤进行: The preparation method of the food having anti-tumor function is carried out according to the following steps:
将本发明的发酵谷物或谷物胚芽提取物以一定的比例加入到发酵乳制品以及其他酸性饮 料中, 制成功能性饮料; 也可将其作为食品配料加入面包、 面条、 香肠以及饼干等食品中; 分离纯化的活性部分直接作为功能食品或进行抗肿瘤药物开发。 The fermented cereal or cereal germ extract of the present invention is added to fermented dairy products and other acidic beverages in a certain ratio to prepare a functional beverage; it can also be added as food ingredients to foods such as bread, noodles, sausages and biscuits. The isolated and purified active fraction is directly used as a functional food or for anti-tumor drug development.
将本发明的发酵谷物或谷物胚芽提取物加入到食品中并无特别的重量要求, 加入量以质 量比计一般为 1%〜15%,优选 4%〜10%;其提取物也可以直接或经过分离纯化后直接作为食 品或药品。 There is no particular weight requirement for adding the fermented cereal or cereal germ extract of the present invention to a foodstuff, and the amount is usually from 1% to 15%, preferably from 4% to 10% by mass; the extract may also be directly or After separation and purification, it is directly used as food or medicine.
本发明的优点: Advantages of the invention:
( 1 )本发明利用自主分离的乳酸菌发酵谷物或谷物胚芽, 制备具有抗肿瘤功能的发酵提
取物, 具有自主知识产权。 (1) The present invention utilizes autonomously isolated lactic acid bacteria to ferment cereal or grain germ to prepare a fermentation extract having anti-tumor function Take the object, with independent intellectual property rights.
(2) 本发明对谷物或谷物胚芽进行简单预处理 (非高温加热), 生产成本低, 采用直投 式发酵, 方便快捷, 安全稳定, 便于质控。 (2) The invention adopts simple pretreatment (non-high temperature heating) on grain or grain germ, has low production cost, adopts direct-injection fermentation, is convenient, fast, safe and stable, and is convenient for quality control.
(3 )本发明以谷物或谷物胚芽为原料, 来源广、 蕴藏量大, 通过对其进行生物转化, 显 著提升谷物或谷物胚芽的生物功能和营养品质, 引导企业应用现代生物技术生产健康、 高值 化产品。 (3) The invention uses cereal or grain germ as raw material, has wide source and large reserves, and bio-transforms it to significantly improve the biological function and nutritional quality of grain or grain germ, and guides enterprises to apply modern biotechnology to produce healthy and high. Valued products.
(4)本发明对提取物中抗肿瘤功活性成分进行了研究, 明确了 40KD以下相对分子质量 的蛋白或多肽具有显著的抗肿瘤功效, 说明乳酸菌发酵过程中蛋白质大分子的适度降解是产 生抗肿瘤活性的重要途径, 同时也为分离纯化后的食品或药品的开发提供了理论依据。 附图说明 (4) The present invention studies the anti-tumor activity active ingredients in the extract, and clarifies that the protein or polypeptide with a relative molecular mass below 40KD has significant anti-tumor effect, indicating that the moderate degradation of protein macromolecules during the fermentation of lactic acid bacteria is resistant. An important pathway for tumor activity, and also provides a theoretical basis for the development of isolated foods or drugs. DRAWINGS
图 1 LFWGE对结肠癌 HT-29细胞的生长抑制率 Figure 1 Growth inhibition rate of LFWGE on colon cancer HT-29 cells
图 2细胞凋亡图谱 Figure 2 Apoptosis map
图 3 LFWGE对结肠癌 HT-29细胞周期的影响 Figure 3 Effect of LFWGE on cell cycle of colon cancer HT-29
图 4 FBE对结肠癌 HT-29细胞的生长抑制率 Figure 4 Growth inhibition rate of FBE on colon cancer HT-29 cells
图 5 LFWGE水溶性蛋白 SDS-PAGE图谱 Figure 5 LFWGE water soluble protein SDS-PAGE map
图 6凝胶过滤层析多肽图谱 Figure 6 gel filtration chromatography peptide map
图 7 FBE中蛋白粗提物和多酚粗提取对 HT-29细胞增殖抑制率 Figure 7: Inhibition of HT-29 cell proliferation by crude extract of crude protein and crude polyphenol extraction in FBE
图 8 LFWGE对荷瘤裸鼠瘤体积的影响 Figure 8 Effect of LFWGE on tumor volume of tumor-bearing nude mice
图 9 LFWGE对荷瘤裸鼠肿瘤的抑制率 Figure 9 Inhibition rate of LFWGE on tumor-bearing nude mice
图 10 LFWGE对荷瘤裸鼠血清中肿瘤坏死因子 -α含量的影响 Figure 10 Effect of LFWGE on the content of tumor necrosis factor-α in serum of tumor-bearing nude mice
图 11 LFWGE对荷瘤裸鼠血清中干扰素 -γ含量的影响 Figure 11 Effect of LFWGE on the content of interferon-γ in serum of tumor-bearing nude mice
图 12 LFWGE对荷瘤裸鼠血清中白细胞介素 -4含量的影响 Figure 12 Effect of LFWGE on serum interleukin-4 content in tumor-bearing nude mice
图 13 LFWGE对 HT-29细胞 CyclinDl、 Bax和 Bcl-2蛋白表达的影响 Figure 13 Effect of LFWGE on the expression of CyclinDl, Bax and Bcl-2 proteins in HT-29 cells
图 14 LFWGE对 HT-29细胞 Caspase-3蛋白表达的影响 Figure 14 Effect of LFWGE on the expression of Caspase-3 protein in HT-29 cells
图 15 FBE对荷瘤裸鼠瘤体积的影响 Figure 15 Effect of FBE on tumor volume of tumor-bearing nude mice
图 16 FBE对荷瘤裸鼠肿瘤的抑制率 Figure 16 Inhibition rate of FBE on tumor-bearing nude mice
图 17 FBE对荷瘤裸鼠肝脏中丙二醛含量的影响 Figure 17 Effect of FBE on the content of malondialdehyde in the liver of nude mice
图 18 FBE对荷瘤鼠肝脏中总超氧化物歧化酶活力的影响 Figure 18 Effect of FBE on the activity of total superoxide dismutase in the liver of tumor-bearing mice
图 19 FBE对荷瘤鼠肝脏中谷胱甘肽过氧化物酶活力的影响 Figure 19 Effect of FBE on the activity of glutathione peroxidase in the liver of tumor-bearing mice
图 20 FBE对荷瘤裸鼠血清中干扰素 -γ的含量的影响 Figure 20 Effect of FBE on the content of interferon-γ in serum of tumor-bearing nude mice
图 21 FBE对荷瘤裸鼠血清中白细胞介素 -4含量的影响
图 22 FBE对荷瘤裸鼠血清中肿瘤坏死因子 -α含量的影响 Figure 21 Effect of FBE on serum interleukin-4 levels in tumor-bearing nude mice Figure 22 Effect of FBE on the content of tumor necrosis factor-α in serum of tumor-bearing nude mice
具体实施方式 detailed description
下面结合实施例对本发明做进一步阐述。 The present invention will be further described below in conjunction with the embodiments.
1.乳酸菌的筛选过程 1. Screening process of lactic acid bacteria
( 1)菌株初筛 (1) Strain screening
首先将采集到的泡菜样品进行适当的梯度稀释, 涂布于 MRS 双层平板法, 恒温箱中于 30°C培养 36h,待菌落长出来后进行观察,观察平板的生长情况,选择平板中菌落合适(30~300 个) 和溶钙圈明显的便于挑取菌落的平板, 记录菌落特征, 选择菌落, 挑取菌落。 Firstly, the collected kimchi samples were appropriately diluted by gradient and applied to the MRS double-layer plate method. The cells were cultured at 30 ° C for 36 h in an incubator. After the colonies grew, observe the growth of the plates and select the colonies in the plates. Appropriate (30~300) and calcium lysate are obvious for easy picking of colonies, record colony characteristics, select colonies, and pick colonies.
再将分离得到的菌株进行多次划线或涂布分离, 以获得纯菌株。 从穿剌保存中挑取少量 菌, 进行革兰氏染色, 通过显微镜观察, 对染色结果进行记录, 检査分得菌株是否是纯菌株, 同时通过对菌株的形状进行观察, 测定细菌大小, 进行初步鉴定。 对不纯的菌再次富集和分 离, 方法同上。 The isolated strain was subjected to multiple scribing or coating separation to obtain a pure strain. Pick a small amount of bacteria from the storage of the sputum, carry out Gram staining, record the staining results by microscopic observation, check whether the strain is a pure strain, and observe the shape of the strain to determine the size of the bacteria. Initial identification. The impure bacteria are again enriched and separated, the method is the same as above.
(2)菌株复筛 (2) strain screening
通过产酸产气试验对分得菌株的产酸能力进行比较, 以获得产酸量高的菌株; 同时通过 观察同时产酸和产气的菌株, 以获得潜在的兼性厌氧乳酸菌。 The acid-producing ability of the obtained strains was compared by the acid-producing gas-producing test to obtain a strain with high acid yield; and the potential facultative anaerobic lactic acid bacteria were obtained by observing the strains which simultaneously produced acid and gas.
根据记录的菌落情况, 选择纯的杆状或链状的革兰氏阳性菌, 在糖发酵产酸培养基进行 产酸产气试验, 接种后恒温箱内 25°C恒温培养 48h, 用 pH计测定其 pH值。 According to the recorded colony conditions, pure rod-shaped or chain-like Gram-positive bacteria were selected, and the acid-producing gas production test was carried out in the sugar-fermented acid-producing medium, and the temperature was incubated at 25 ° C for 48 hours in the incubator after inoculation. The pH was measured.
2.菌种鉴定 2. Identification of strains
( 1 )形态学观察 (1) Morphological observation
从自然发酵的甘蓝泡菜中分离出三株产酸量最大的菌株, 在固体培养基上呈现出白色菌 落凸起、 圆形、 边缘整齐、 表面光滑的特征; 在液体培养基中兼性厌氧, 生长到一定数量呈 混浊状; 革兰氏染色观察 (见表 1 )均为氏阳性, 菌体圆端直杆状, 宽 0.8~1.2μηι, 长 1~2μηι 单个或成对排列, 不形成内生芽孢。 Three strains with the highest acid yield were isolated from naturally fermented cabbage kimchi, showing white colony bulge, round, tidy edges and smooth surface on solid medium; facultative anaerobic in liquid medium , growth to a certain amount of turbidity; Gram stain observation (see Table 1) are positive, the bacterial body rounded straight rod shape, width 0.8~1.2μηι, length 1~2μηι single or in pairs, not formed Endogenous spores.
(2)生理生化试验 (2) Physiological and biochemical tests
对上述三株菌株进行生理生化试验 (见表 2) 结果表明, 三株菌的精氨酸产氨试验、 产 硫化氢试验、 过氧化氢酶试验、 明胶液化试验、 硝酸盐还原试验和吲哚试验均为阴性; 乳酸 定性试验显示, 均产生乳酸; 在糖发酵试验中 (见表 3 ) 不发酵鼠李糖, 部分弱发酵阿拉伯 糖和松三糖, 其余的糖醇均能发酵, 均不产气。 生理生化试验鉴定该三株菌都是植物乳杆菌 (Lactobacillus Plantarum)。 但仍有必要选择发酵性能较好的 Dy-1进行 16s rDNA扩增进行 进一步的鉴定。
(3) 16s rDNA PCR扩增产物序列 Physiological and biochemical tests on the above three strains (see Table 2) showed that the three strains of arginine ammonia production test, hydrogen sulfide production test, catalase test, gelatin liquefaction test, nitrate reduction test and 吲哚The test was negative; lactic acid qualitative test showed that lactic acid was produced; in the sugar fermentation test (see Table 3), no fermented rhamnose, partially weakly fermented arabinose and pine triose, the other sugar alcohols could be fermented, neither Produce gas. Physiological and biochemical tests identified the three strains as Lactobacillus Plantarum. However, it is still necessary to select Dy-1 with better fermentation performance for 16s rDNA amplification for further identification. (3) 16s rDNA PCR amplification product sequence
挑取 Dy-1菌适量,加入 MRS培养基中, 37°C培养过夜,取 ImL菌液, 5000xg离心 5min, 弃去上清液后加入 300μί细胞裂解液和 50μί蛋白酶 Κ, 90 °C水浴裂解 lOmin后, 12000xg 离心 lOmin取上清液, 以 v3通用引物进行 PCR反应。 Pick the appropriate amount of Dy-1 bacteria, add it to MRS medium, incubate at 37 °C overnight, take 1mL of bacterial solution, centrifuge at 5000xg for 5min, discard the supernatant, add 300μί cell lysate and 50μί protease, and lyse at 90 °C in water bath. After lOmin, the supernatant was taken at 12000 xg for 10 min, and the PCR reaction was carried out with the v3 universal primer.
PCR产物纯化后交由上海生工测序, 序列如下: The PCR product was purified and sequenced by Shanghai Biotech. The sequence is as follows:
CAAGAGCCTGTCAGC
通过在 Genbank中 Blast分析结果可知, Dy- 1 的 16S rRNA基因序列与 Lactobacillus plantar um strain L3的 16S rRN A基因序列只有 3个碱基的差异, 其相似性达 99%以上, 应属 于同一种, 即 Lactobacillus plantarum。 该菌株于 2012年 4月 18日送交位于中国北京市朝阳 区北辰西路 1号院 3号的中国科学院微生物研究所的中国微生物菌种保藏管理委员会普通微 生物中心保藏,保藏编号为 CGMCC No.6016,其建议的分类名称为植物乳杆菌, Lactobacillus plantar 称其为乳酸菌 Dy- 1 CAAGAGCCTGTCAGC According to the results of Blast analysis in Genbank, the 16S rRNA gene sequence of Dy-1 is only 3 bases different from the 16S rRN A gene sequence of Lactobacillus plantar um strain L3, and its similarity is more than 99%, which should belong to the same species. That is Lactobacillus plantarum. The strain was deposited on April 18, 2012 at the General Microbiology Center of the China Microbial Culture Collection Management Committee of the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Beichen West Road, Chaoyang District, Beijing, China. The deposit number is CGMCC No. 6016, its suggested classification name is Lactobacillus plantarum, Lactobacillus plantar called it lactic acid bacteria Dy-1
3. 抗肿瘤功能试验 3. Anti-tumor function test
体外抗肿瘤功能: 将本发明的发酵谷物或谷物胚芽提取物以 0.125 4mg/mL的浓度加入 到人的 HT-29结肠癌细胞中, 培养一段时间 (如 48h) 后, 观察评价其抗肿瘤效果。 其方法 如下- In vitro anti-tumor function: The fermented cereal or cereal germ extract of the present invention is added to human HT-29 colon cancer cells at a concentration of 0.125 4 mg/mL, and cultured for a period of time (for example, 48 hours), and the anti-tumor effect is observed and evaluated. . The method is as follows -
①细胞增殖试验: 采用 MTT法。 1 Cell proliferation assay: MTT method was used.
②细胞凋亡与细胞周期试验: 采用流式细胞仪进行分析。 2 Apoptosis and cell cycle assay: Flow cytometry was used for analysis.
与未加本发明发酵谷物或谷物胚芽提取物的对照相比较, 肿瘤活细胞数可降至 50%或以 下, 最优的可使活细胞数降至 10%或以下; 其肿瘤凋亡率可达 50%或以上, 最高可达 90%或 以上。 Compared with the control without the fermented cereal or cereal germ extract of the present invention, the number of living cells of the tumor can be reduced to 50% or less, and the number of living cells can be optimally reduced to 10% or less; Up to 50% or more, up to 90% or more.
体内抗肿瘤功能:将 4 6周龄的 BALB/c 裸鼠的腹部皮下接种人结肠癌 HT-29细胞(接 种量: 1 106 2 107细胞/裸鼠), 2 15天后肉眼可见裸鼠接种部位有肿瘤长出后开始灌胃; 将荷瘤裸鼠随机分成 5组, 即阴性对照组、 5-FU阳性对照组、 高剂量组、 低剂量组和高剂量 组 +5-FU组, 每组 10 12只裸鼠, 连续灌胃 14 50天; 每日测定瘤体积, 绘制肿瘤生长曲 线, 根据肿瘤重量计算抑瘤率; 在试验末期测定荷瘤裸鼠血清中干扰素 (IFN-Y)、 白介素 -4 ( IL-4) 和肿瘤坏死因子 (TNF-a)的浓度。 结果表明, 与阴性对照组相比较, 灌胃发酵谷物或 谷物胚芽提取物组的抑瘤率可达 30% 60% In vivo anti-tumor function: The abdominal cancer of 46-week-old BALB/c nude mice was subcutaneously inoculated into human colon cancer HT-29 cells (inoculation amount: 1 10 6 2 10 7 cells/nude mice), and nude mice were visually observed after 2 15 days. At the inoculation site, the tumor was started and the stomach was started. The tumor-bearing nude mice were randomly divided into 5 groups, namely, the negative control group, the 5-FU positive control group, the high dose group, the low dose group, and the high dose group +5-FU group. 10 12 nude mice in each group were continuously intragastrically administered for 14 50 days; the tumor volume was measured daily, the tumor growth curve was drawn, and the tumor inhibition rate was calculated according to the tumor weight; the interferon (IFN- Y) in the serum of the tumor-bearing nude mice was determined at the end of the experiment. ), the concentration of interleukin-4 (IL-4) and tumor necrosis factor (TNF-a). The results showed that the inhibition rate of the fermented cereal or grain extract group was 30% 60% compared with the negative control group.
实施例 1 Example 1
称取粉碎的新鲜小麦胚芽(以下简称麦胚)粉 20.0g于 500mL锥形瓶中,向其中加入 100ml 的蒸馏水, 再加入 0.4g的乳酸菌 Dy-1发酵剂, 混合均匀; 将锥形瓶用纱布封口, 置于恒温 培养箱中在 30°C下发酵 24h后, 将其在 6500g/min下离心 20min收集上清液进行冷冻干燥。 Weigh 20.0g of pulverized fresh wheat germ (hereinafter referred to as wheat germ) powder in a 500mL Erlenmeyer flask, add 100ml of distilled water to it, add 0.4g of lactic acid bacteria Dy-1 starter, mix evenly; The gauze was sealed and placed in a constant temperature incubator for 24 hours at 30 ° C. After centrifugation at 6500 g / min for 20 min, the supernatant was collected and lyophilized.
称取 0.5g的冻干粉 (LFWGE) 溶于 50ml的去离子水中, 过 0.22um的滤膜, 将滤液按 照 0.125 mg/mL 0.25mg/mL 0.5 mg/mL 1.0 mg/mL 2.0 mg/mK 4.0 mg/ml分别加入到 HT-29 结肠癌细胞中, 培养细胞 24h 48h 72h, 并分别通过 MTT法测定 LFWGE对结肠癌 HT-29 细胞的抑制率 (图 1 )。 结果表明, 提取物浓度与肿瘤细胞增殖抑制率呈正相关, 最大抑制率 达到 94.2%
将 1.0mg/mL的 LFWGE加入到结肠癌细胞中, 培养细胞 48h后, 收集细胞, 流式细胞仪 检测细胞凋亡(图 2)。结果表明, 早期凋亡是 66.5% (图 2, 右下角), 晚期凋亡是 27.6% (图 2, 右上角)。 将 0.2mg/mL、 0.4 mg/mL、 0.8mg/mL的 LFWGE加入到结肠癌 HT-29细胞中, 培养细胞 48h后, 收集细胞, 流式细胞仪检测细胞周期(图 3 )。 结果表明, 随着浓度的增加, 01期也随之延长, 而 S期则随之缩短, 说明 LFWGE能有效阻滞细胞的 期。 Weigh 0.5g of lyophilized powder (LFWGE) dissolved in 50ml of deionized water, pass 0.22um filter, and the filtrate is 0.125 mg/mL 0.25mg/mL 0.5 mg/mL 1.0 mg/mL 2.0 mg/mK 4.0 Mg/ml was added to HT-29 colon cancer cells, cultured for 24 h, 48 h, 72 h, and the inhibition rate of LFWGE on colon cancer HT-29 cells was determined by MTT assay (Fig. 1). The results showed that the concentration of extract was positively correlated with the inhibition rate of tumor cell proliferation, and the maximum inhibition rate reached 94.2%. 1.0 mg/mL of LFWGE was added to colon cancer cells, and after 48 hours of cell culture, cells were collected, and apoptosis was detected by flow cytometry (Fig. 2). The results showed that early apoptosis was 66.5% (Fig. 2, lower right corner) and late apoptosis was 27.6% (Fig. 2, upper right corner). LFWGE of 0.2 mg/mL, 0.4 mg/mL, and 0.8 mg/mL was added to colon cancer HT-29 cells, and cells were cultured for 48 hours, and the cells were collected, and the cell cycle was detected by flow cytometry (Fig. 3). The results showed that with the increase of concentration, the 0 1 phase also prolonged, and the S phase shortened, indicating that LFWGE can effectively block the cell phase.
实施例 2 Example 2
取实施例 1中的滤液同样以 0.125 mg/mL、 0. 25mg/ml、 0. 5 mg/mK 1.0 mg/mK 2.0 mg/mK 4.0 mg/ml分别加入到 SGC-7901胃癌细胞中, 培养细胞 24h、 48h、 72h, 并分别通过 MTT法 测定 LFWGE对胃癌 SGC-7901细胞的抑制率。 结果表明, 提取物浓度与肿瘤细胞增殖抑制 率呈正相关, 最大抑制率达到 89.6%。 The filtrate in Example 1 was also added to SGC-7901 gastric cancer cells at 0.125 mg/mL, 0.25 mg/ml, 0.5 mg/mK 1.0 mg/mK 2.0 mg/mK 4.0 mg/ml, respectively. At 24h, 48h, 72h, the inhibition rate of LFWGE on gastric cancer SGC-7901 cells was determined by MTT assay. The results showed that the concentration of extract was positively correlated with the inhibition rate of tumor cell proliferation, and the maximum inhibition rate reached 89.6%.
将 lmg/ml的 LFWGE加入到 SGC-7901胃癌细胞中, 培养细胞 48h后, 收集细胞, 流式 细胞仪检测细胞的凋亡。 早期凋亡是 48.5%, 晚期凋亡是 22.4%。 将 0.2mg/ml、 0.4 mg/ml、 0.8mg/ml的 LFWGE加入到胃癌细胞中, 培养细胞 48h后, 收集细胞, 流式细胞仪检测细胞 周期。 结果表明, 随着浓度的增加, 01期也随之延长, 而 S期则随之缩短, 说明 LFWGE能 有效阻滞细胞的01期。 The lmg/ml LFWGE was added to the SGC-7901 gastric cancer cells, and the cells were cultured for 48 hours, and the cells were collected, and the apoptosis of the cells was detected by flow cytometry. Early apoptosis was 48.5% and late apoptosis was 22.4%. LFWGE of 0.2 mg/ml, 0.4 mg/ml, and 0.8 mg/ml was added to gastric cancer cells, and the cells were cultured for 48 hours, and the cells were collected, and the cell cycle was detected by flow cytometry. The results showed that with the increase of concentration, the phase 1 was also prolonged, and the S phase was shortened, indicating that LFWGE can effectively block the phase 1 of cells.
实施例 3 Example 3
称取粉碎过 60目筛的大麦粉 20.0g于 500mL锥形瓶中, 向其中加入 1:6比例的水混合均 匀,可用 0.015%的 β-葡聚糖酶 40°C水解 30min或不水解,加入 4%乳酸菌 Dy-1发酵剂在 30°C 下发酵 48h, 发酵完成后将发酵产物在室温下 5000g/min离心 20min, 收集上清液, 并将其进 行冷冻干燥 24h, 从而获得发酵大麦提取物 (FBE)。 20.0 g of barley flour crushed through a 60 mesh sieve was weighed into a 500 mL Erlenmeyer flask, and a 1:6 ratio of water was added thereto to be uniformly mixed, and the mixture was hydrolyzed with 0.015% β-glucanase at 40 ° C for 30 min or not. Fermentation was carried out at 30 °C for 48 h by adding 4% lactic acid bacteria Dy-1 starter. After the fermentation was completed, the fermentation product was centrifuged at 5000 g/min for 20 min at room temperature, and the supernatant was collected and freeze-dried for 24 h to obtain fermented barley extract. (FBE).
称取 0.5g的 FBE溶于 50ml的去离子水中,过 0.22um的滤膜,将滤液按照 0.125 mg/mL 、 0.25mg/mL、 0.5 mg/mL、 1.0 mg/mL、 2.0 mg/ml、 4.0 mg/ml分别加入到 HT-29肿瘤细胞中, 培养细胞 24h、 48h、 72h, 并分别通过 MTT法测定 FBE对结肠癌 HT-29细胞的抑制率。 结 果表明, 提取物浓度与肿瘤细胞增殖抑制率呈正相关, 最大抑制率达到 95.6% (图 4)。 Weigh 0.5g of FBE dissolved in 50ml of deionized water, pass 0.22um filter, and the filtrate is 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 1.0mg/mL, 2.0mg/ml, 4.0 Mg/ml was added to HT-29 tumor cells, cultured for 24h, 48h, 72h, and the inhibition rate of FBE on colon cancer HT-29 cells was determined by MTT assay. The results showed that the extract concentration was positively correlated with the inhibition rate of tumor cell proliferation, and the maximum inhibition rate reached 95.6% (Fig. 4).
实施例 4 Example 4
100g粉碎的新鲜麦胚加入 1L的蒸馏水和 4g的乳酸菌 Dy-1发酵剂混合均匀, 混合物在 250rpm的转速下 30°C发酵 48h。 所得发酵产物进行 6000g离心 15min, 上清液被收集并进行 冷冻干燥,获得 LFWGE冻干粉。利用 SDS-PAGE检测 LFWGE中水溶性蛋白的分布(图 5)。 为了分离 LFWGE中蛋白成分, 采用 (NH4)2S04沉淀法将 LFWGE水溶液中的蛋白沉淀析出, 沉淀溶解在 PBS中, 并将所得的溶液通过 SephadexG-50和 SurpedexS-200凝胶过滤层析, 分 别收集峰 1和峰 2两个部分 (图 6), 并将其分别冷冻干燥。 采用 MTT法分别测定了峰 1和
峰 2组分对 HT-29细胞的抑制率。 结果表明, 峰 1对 HT-29细胞具有显著的抑制率, 最大可 达到 88.6% (表 3 )。 100 g of pulverized fresh wheat germ was mixed with 1 L of distilled water and 4 g of lactic acid bacteria Dy-1 starter, and the mixture was fermented at 30 ° C for 48 h at 250 rpm. The obtained fermentation product was centrifuged at 6000 g for 15 min, and the supernatant was collected and freeze-dried to obtain a LFWGE lyophilized powder. The distribution of water-soluble proteins in LFWGE was detected by SDS-PAGE (Fig. 5). In order to separate the protein components in LFWGE, the protein in the LFWGE aqueous solution was precipitated by (NH4) 2 S0 4 precipitation method, the precipitate was dissolved in PBS, and the resulting solution was subjected to gel filtration chromatography on Sephadex G-50 and Surpedex S-200. Peaks 1 and 2 were collected separately (Figure 6) and lyophilized separately. Peak 1 and 1 were determined by MTT method The inhibition rate of the peak 2 component on HT-29 cells. The results showed that peak 1 had a significant inhibition rate on HT-29 cells, with a maximum of 88.6% (Table 3).
实施例 5 Example 5
100g粉碎的新鲜大麦加入 1L的蒸馏水和 4g的乳酸菌 Dy-1发酵剂混合均匀, 混合物在 250rpm的转速下, 30°C发酵 24h。 所得发酵产物进行 5000g离心 15min, 上清液被收集并进 行冷冻干燥, 获得发酵大麦提取物 (FBE)冻干粉。 溶解 FBE, 并用 90%饱和度的 (NH4)2S04 沉淀蛋白, 6000g/min离心 15min, 取沉淀用蒸馏水溶解后用分子量 8000-14000Da的透析袋 透析 3次, 冻干后得蛋白粗提物。 称 lg FBE, 用 70%乙醇料液比 1 : 60, 60°C回流浸提 lh, 提取 2次, 4500g/min离心 15min得滤液, 经旋转蒸发得浓缩液, 冷冻干燥, 得多酚粗提物。 将 500ug/mL的蛋白粗提物与多酚粗提物加入到 HT-29肿瘤细胞中, 培养细胞 24h后, 并通 过 MTT法测定蛋白粗提物与多酚粗提物对结肠癌 HT-29细胞的抑制率。 结果表明, 蛋白粗 提物和多酚粗提物与肿瘤细胞增殖抑制率呈正相关 (图 7)。 100 g of pulverized fresh barley was mixed with 1 L of distilled water and 4 g of lactic acid bacteria Dy-1 starter, and the mixture was fermented at 250 rpm for 24 h at 30 °C. The obtained fermentation product was centrifuged at 5000 g for 15 min, and the supernatant was collected and freeze-dried to obtain a fermented barley extract (FBE) lyophilized powder. The FBE was dissolved, and the protein was precipitated with 90% saturation of (NH 4 ) 2 S0 4 , centrifuged at 6000 g/min for 15 min, and the precipitate was dissolved in distilled water and dialyzed 3 times with a dialysis bag having a molecular weight of 8000-14000 Da. After lyophilization, the protein was coarsely extracted. Things. Weigh lg FBE, using 70% ethanol solution ratio 1:60, 60 ° C reflux leaching lh, extract 2 times, centrifuge at 4500g / min for 15min to obtain the filtrate, rotary evaporation to obtain a concentrated solution, freeze-dried, much phenol crude Things. 500 ug/mL crude protein extract and crude polyphenol extract were added to HT-29 tumor cells, and the cells were cultured for 24 hours, and the crude protein extract and polyphenol crude extract were determined by MTT method for colon cancer HT-29. Cell inhibition rate. The results showed that crude protein extract and crude polyphenol extract were positively correlated with tumor cell proliferation inhibition rate (Fig. 7).
实施例 ό Example ό
将上述制备的 LFWGE溶解于生理盐水中, 制备成浓度为 0.2g/ml和 0.1g/ml水溶液, 并 通过无菌膜处理备用。人 HT-29结肠癌细胞接种到 4-6周龄的 BALB/c裸鼠腹部皮下, 2天后 采用 2g/kg/d、 lg/kg/d、 2g/kg/d+5-FU (25 mg/kg/d, i.p, 7天) 剂量的 LFWGE给荷瘤裸鼠灌 胃, 连续灌胃 30天, 同时与灌胃相同剂量的生理盐水组和腹腔注射 5-FU组(25 mg/kg/d, i.p, 7天)进行比较, 通过测定瘤体积的变化和最后的抑瘤率来确定 LFWGE的抗肿瘤效果(图 8 和图 9 )。结果表明, 2g/kg/d、 lg/kg/d、 2g/kg/d+5-FU LFWGE剂量组的抑瘤率分别达到 49.37%、 40.7%、 47.8%。 The LFWGE prepared above was dissolved in physiological saline to prepare an aqueous solution having a concentration of 0.2 g/ml and 0.1 g/ml, and was treated by a sterile membrane for use. Human HT-29 colon cancer cells were inoculated subcutaneously into 4-6 weeks old BALB/c nude mice, and 2 days later, 2g/kg/d, lg/kg/d, 2g/kg/d+5-FU (25 mg) /kg/d, ip, 7 days) The dose of LFWGE was administered to the tumor-bearing nude mice for 30 days of continuous gavage, and the same dose of saline group and intraperitoneal injection of 5-FU group (25 mg/kg/). d, ip, 7 days) Comparison was performed to determine the antitumor effect of LFWGE by measuring changes in tumor volume and final tumor inhibition rate (Figures 8 and 9). The results showed that the tumor inhibition rates of 2g/kg/d, lg/kg/d, 2g/kg/d+5-FU LFWGE group reached 49.37%, 40.7%, and 47.8%, respectively.
用酶联免疫试剂盒测定荷瘤裸鼠血清中肿瘤坏死因子(TNF-a)、 干扰素(IFN-γ)及白细 胞介素 -4 (IL-4) 的含量。 结果表明, LFWGE使荷瘤裸鼠血清中 IFN 、 IL-4以及 TNF-α的 含量显著增加 (图 10、 图 11和图 12), 与其对 HT-29结肠癌细胞产生抑制作用有关。 The levels of tumor necrosis factor (TNF-a), interferon (IFN-γ) and interleukin-4 (IL-4) in the serum of tumor-bearing nude mice were determined by enzyme-linked immunosorbent assay kit. The results showed that LFWGE significantly increased the levels of IFN, IL-4 and TNF-α in the serum of tumor-bearing nude mice (Fig. 10, Fig. 11 and Fig. 12), which was related to the inhibition of HT-29 colon cancer cells.
用免疫印迹测定荷瘤裸鼠肿瘤组织中相关因子的表达, 发现 LFWGE 可下调 Bcl-2、 CyclinDl的 mRNA及蛋白表达; 上调 Bax和 Caspase-3的 mRNA及蛋白表达(图 13,14), 从 而诱导荷瘤裸鼠肿瘤细胞的凋亡。 The expression of related factors in tumor tissues of nude mice was determined by immunoblotting. It was found that LFWGE down-regulated the mRNA and protein expression of Bcl-2 and CyclinDl; up-regulated the mRNA and protein expression of Bax and Caspase-3 (Fig. 13, 14). Induction of apoptosis in tumor cells of nude mice bearing tumors.
实施例 7 Example 7
将上述制备的 FBE溶解于生理盐水中, 制备成浓度为 0.2g/ml和 0.1g/ml, 并且通过无菌 膜处理备用。 将人的 HT-29结肠癌细胞接种到 4-6周龄的 BALB/c裸鼠腹部皮下, 2天后采用 2g/kg/d、 lg/kg/d、 2g/kg/d+5-FU (25 mg/kg/d, i.p, 7天) 剂量的 FBE给荷瘤裸鼠灌胃, 连续 灌胃 30天, 同时与灌胃相同剂量的生理盐水组和腹腔注射 5-FU组 (25 mg/kg/d, 7天) 作比
较,通过用游标卡尺测量的移植瘤体积和最后的抑瘤率来确证 FBE的抗肿瘤作用(图 15,16)。 结果表明, 2g/kg/d+5-FU混合剂量组的抑瘤率可达到 53.36%。 The FBE prepared above was dissolved in physiological saline to a concentration of 0.2 g/ml and 0.1 g/ml, and was treated by a sterile membrane for use. Human HT-29 colon cancer cells were inoculated subcutaneously into 4-6 week old BALB/c nude mice, and 2 days later, 2g/kg/d, lg/kg/d, 2g/kg/d+5-FU ( 25 mg/kg/d, ip, 7 days) The dose of FBE was administered to the tumor-bearing nude mice for 30 days, and the same dose of saline group and intraperitoneal injection of 5-FU group (25 mg/). Kg/d, 7 days) In contrast, the antitumor effect of FBE was confirmed by the volume of the transplanted tumor measured by the vernier caliper and the final tumor suppressing rate (Fig. 15, 16). The results showed that the inhibition rate of the 2g/kg/d+5-FU mixed dose group could reach 53.36%.
用试剂盒测定荷瘤裸鼠肝脏中超氧化物歧化酶 (SOD) (图 17)、 谷胱甘肽 -过氧化物酶 (GSH-PX)(图 18)和丙二醛(MDA)的含量(图 19)。结果表明 FBE可以增加 SOD和 GSH-PX 的酶活, 降低 MDA的含量。 The contents of superoxide dismutase (SOD) (Fig. 17), glutathione-peroxidase (GSH-PX) (Fig. 18) and malondialdehyde (MDA) in the liver of tumor-bearing nude mice were determined by kit ( Figure 19). The results show that FBE can increase the enzyme activity of SOD and GSH-PX and decrease the content of MDA.
用酶联免疫试剂盒测定荷瘤裸鼠血清中干扰素 (IFN-γ) ((图 20)、 白介素 -4 (图 21) 和 肿瘤坏死因子 (TNF-α) (图 22) 的浓度。 结果表明, FBE可以同时增加 IFN-Y、 白介素 -4以及 TNF-α的含量。 The concentration of interferon (IFN-γ) (Fig. 20), interleukin-4 (Fig. 21) and tumor necrosis factor (TNF-α) (Fig. 22) in the serum of tumor-bearing nude mice was determined by enzyme-linked immunosorbent assay kit. show, FBE simultaneously can be increased IFN- Y, the content of interleukin-4 and TNF-α in.
表 1 筛选获得产酸量最高菌株的形态学特征 Table 1 Screening to obtain the morphological characteristics of the strain with the highest acid yield
代号 pH值 滴定酸度 (%) 特征 细菌大小 (μηι) 纯否 Code pH Titration Acidity (%) Characteristics Bacterial Size (μηι) Pure No
3.70 0.528 杆状 0.8X1.1 纯 3.70 0.528 rod shape 0.8X1.1 pure
3.70 0.528 杆状 0.8X1.2 纯3.70 0.528 rod shape 0.8X1.2 pure
3.69 0.528 杆状 0.8X1.0 纯 3.69 0.528 rod shape 0.8X1.0 pure
表 2 分离出的菌株的生理生化试验结果 Table 2 Physiological and biochemical test results of isolated strains
代号 精氨酸产氨试验 产硫化氢 过氧化氢酶 明胶液化 硝酸盐还原 吲哚试验 Code arginine ammonia production test hydrogen sulfide hydrogen peroxide enzyme gelatin liquefaction nitrate reduction 吲哚 test
试验 试验 试验 试验 Test test test
DY-1 DY-1
s3 注: +代表阳性, 一代表阴性 s 3 Note: + means positive, one means negative
表 3 LFWGE中两部分多肽对 HT-29细胞增殖抑制率 样品 浓度 ( g/mL) 吸光度 (A490) 抑制率 (%) Table 3 Inhibition rate of two-part peptides in LFWGE against HT-29 cells Sample Concentration (g/mL) Absorbance (A490) Inhibition rate (%)
200 0.100±0.012 88.6 200 0.100±0.012 88.6
100 0.381 ±0.021 56.8 100 0.381 ±0.021 56.8
pe kl 50 0.432±0.015 51.0 Pe kl 50 0.432±0.015 51.0
25 0.631 ±0.024 28.4
200 0.873 ± 0.052 0.925 0.631 ±0.024 28.4 200 0.873 ± 0.052 0.9
100 0.861 + 0.073 23100 0.861 + 0.073 23
50 0.892±0.017 -1.250 0.892 ± 0.017 - 1.2
25 0.871 ±0.013 1.1
25 0.871 ±0.013 1.1
SEQUENCE LISTINGSEQUENCE LISTING
<110> 江苏大学 <110> Jiangsu University
<120> 乳酸菌及发酵谷物或谷物胚芽提取物的制备方法与用途 <120> Preparation method and use of lactic acid bacteria and fermented cereal or cereal germ extract
<160> 1 <160> 1
<170> Patentln version 3.3 <170> Patentln version 3.3
请按照 "注意事项"正确填写本表各栏 第②和第④栏未确定的由专利局填写 来源 Please follow the "Precautions" to correctly fill in the fields that are not determined by the Patent Office in columns 2 and 4 of the columns of this table.
发明名称 乳酸菌及发酵谷物或谷物胚芽提取物的制备 ① 申请号 Title: Preparation of Lactic Acid Bacteria and Fermented Cereal or Grain Germ Extract 1 Application No.
方法与用途 Method and use
方方式式 Square mode
② 申请人 江苏大学 ③ 申请日 2 Applicant Jiangsu University 3 Application Date
④ 遗传资源名称: 植物乳杆菌 Lactobacillus plantarum 4 Name of genetic resources: Lactobacillus plantarum Lactobacillus plantarum
⑥遗传资源的获取途径 6 Access to genetic resources
I 遗传资源取自: □动物 □植物 微生物 口人 I Genetic resources are taken from: □ animals □ plants microbes
II 获取方式: □购买 □赠送或交换 口保藏机构 □种子库 (种质库) 口基因文库 図自行采 集 □委托采集 □其他 II Acquisition method: □ Purchase □ Gift or exchange Port depository □ Seed bank (species bank) Oral gene library 図 Self-collection □ Entrusted collection □ Others
⑧获取时间 2012年 2 月 8Get the time February 2012
⑨提供者名称 9 provider name
(姓名) (name)
非 Non
⑩提供者所处 10 providers are located
国家或地区 Country or region
⑦ 7
Θ提供者联系 Θ Provider contact
方式 the way
©采集地 (国 © collecting place (country
中国 江苏省 镇江市 江苏大学 China Jiangsu Province Zhenjiang City Jiangsu University
家、 省 (市)) Home, province (city))
Θ采集者名称 Θ Collector Name
(姓名) (name)
Θ采集者联系 Θ Collector contact
13505280069 13505280069
方式 the way
© 采集者名 © Collector Name
称 (姓名) (name)
© 采集者联 © Collector
13505280069 13505280069
系方式 System mode
©原始来源 © original source
(@获取时间 2012年 2 月 (@Get the time February 2012
©获取地点 © Get location
( 国家、 省 中国 江苏省 镇江市 江苏大学校园内实验室 (市)) (Country, Province China Jiangsu Province Zhenjiang City Jiangsu University Campus Laboratory (City))
©无法说明遗传资源原始来源的理由: © Reasons why the original source of genetic resources cannot be stated:
@全体申请人或专利代理机构签字或者盖章 ©专利局处理意见 @Signature or seal of all applicants or patent agencies © Patent Office
2013年 6月 5日 年 月 日
June 5, 2013
Claims
1、 乳酸菌 Dy-1, 其建议的分类名称为植物乳杆菌, Lactobacillus plantarum; 保藏编号为 CGMCC No.6016。 1. Lactobacillus Dy-1, its proposed classification name is Lactobacillus plantarum; the deposit number is CGMCC No.6016.
2、 乳酸菌发酵谷物或谷物胚芽提取物的制备方法, 其特征在于按照下述步骤进行: 2. A method for preparing lactic acid bacteria fermented cereal or cereal germ extract, which is characterized by following the following steps:
( 1)菌种的选择: 选择植物乳杆菌 ·σ<:ί:ο/5σ(:/7/υ5 ρ/σηί:σ ·υΜ, CGMCC No.6016; 或选择商 用优良乳酸菌, 如植物乳杆菌 (Lactobacillus plantarum)、 短乳杆菌 (Lactobacillus brevis)、 嗜酸乳杆菌 (Lactobacillus acidophilus )、 干酪乳杆菌 (Lactobacillus case) 中的一种或几种为 出发菌株; (1) Selection of strains: Choose Lactobacillus plantarum·σ<:ί:ο/5σ(:/7/υ5 ρ/σηί:σ ·υΜ, CGMCC No.6016; or choose commercially available excellent lactic acid bacteria, such as Lactobacillus plantarum One or more of Lactobacillus plantarum, Lactobacillus brevis, Lactobacillus acidophilus and Lactobacillus case is the starting strain;
(2)乳酸菌发酵谷物或谷物胚芽及其发酵提取物的制备:称取筛分除杂后的谷物或谷物 胚芽, 粉碎过 30〜140目筛, 置于锥形瓶中, 按照质量与体积比 1:6~1: 15比例, 优选 1:7的 比例加入蒸馏水, 再加入乳酸菌 Dy-1发酵剂到谷物或谷物胚芽中, 其中乳酸菌 Dy-1发酵剂 占新鲜谷物或谷物胚芽粉的质量为 2~8%, 混合均匀; 将锥形瓶用纱布封口, 置于恒温培养箱 中, 在 20〜40°C下发酵 12〜72h, 其中优选发酵温度 30〜35°C, 发酵 24〜48 h后, 发酵物在 室温下 3000〜12000g/min离心 10〜40min, 其中优选 5000〜6500g/min离心 20〜30min; 收 集上清液, 并将其进行热风干燥、 喷雾干燥或冷冻干燥, 优选冷冻干燥, 从而获得发酵谷物 或谷物胚芽的提取物; (2) Preparation of grains or grain germs fermented by lactic acid bacteria and fermentation extracts: weigh the grains or grain germs after screening and impurity removal, crush them through a 30 to 140 mesh sieve, place them in an Erlenmeyer flask, and mix according to the mass to volume ratio. Add distilled water at a ratio of 1:6~1:15, preferably 1:7, and then add lactic acid bacteria Dy-1 starter to the grain or grain germ, where the lactic acid bacteria Dy-1 starter accounts for the mass of fresh grain or grain germ powder. 2~8%, mix evenly; seal the Erlenmeyer flask with gauze, place it in a constant temperature incubator, and ferment at 20~40°C for 12~72h, with the preferred fermentation temperature being 30~35°C and fermentation for 24~48 h. Afterwards, the fermentation product is centrifuged at room temperature at 3000~12000g/min for 10~40min, preferably at 5000~6500g/min for 20~30min; the supernatant is collected and subjected to hot air drying, spray drying or freeze drying, preferably freeze drying. , thereby obtaining an extract of fermented grains or grain germ;
(3)乳酸菌发酵谷物或谷物胚芽提取物的分离纯化: 采用硫酸铵沉淀、 高效液相(流动 相是甲醇与水的比例按照 20%〜15%, 流速为 lm!Jmin, 柱温为 25°C, 检测波长为 288nm。)、 凝胶过滤层析 (SephadexG-50禾 P SurpedexS-200)、 SDS-PAGE ( 5%的浓缩胶, 10%〜 12%的 分离胶) 对发酵谷物或谷物胚芽提取物进行分离纯化, 即可得到乳酸菌发酵谷物或谷物胚芽 提取物中的蛋白或多肽。 (3) Separation and purification of lactic acid bacteria fermented grains or grain germ extracts: ammonium sulfate precipitation, high-performance liquid phase (the mobile phase is methanol and water in a ratio of 20% to 15%, the flow rate is lm!Jmin, and the column temperature is 25° C, the detection wavelength is 288nm.), gel filtration chromatography (SephadexG-50 and SurpedexS-200), SDS-PAGE (5% stacking gel, 10%~12% separation gel) for fermented cereals or cereal germs The extract is separated and purified to obtain the protein or peptide in the lactic acid bacteria fermented grain or grain germ extract.
3、 根据权利要求 1所述的乳酸菌发酵谷物或谷物胚芽提取物的制备方法, 其特征在于其 中步骤 (1 ) 中选用的乳酸菌采用 MRS液体培养基活化和高密度培养后, 添加保护剂, 以质 量比为: 20%脱脂乳、 10%海藻糖、 14%谷氨酸钠、 6%山梨醇和 6%Vc,或者以质量比计为 22% 菊粉、 12%谷氨酸钠和 5%山梨醇后采用真空冷冻干燥法制备可直接使用的乳酸菌 Dy-1发酵 剂, 分装于无菌真空包装袋中密封保藏待用。 3. The method for preparing lactic acid bacteria fermented cereals or cereal germ extract according to claim 1, characterized in that the lactic acid bacteria selected in step (1) are activated and cultured at high density using MRS liquid culture medium, and then a protective agent is added to The mass ratio is: 20% skim milk, 10% trehalose, 14% sodium glutamate, 6% sorbitol and 6% Vc, or the mass ratio is 22% inulin, 12% sodium glutamate and 5% sorbitol. After alcoholization, vacuum freeze-drying method is used to prepare lactic acid bacteria Dy-1 starter culture that can be used directly, and the fermentation agent is sealed and stored in sterile vacuum packaging bags for later use.
4、 根据权利要求 1所述的乳酸菌发酵谷物或谷物胚芽提取物的制备方法, 其特征在于其 中所述的谷物为大麦或者薏米、 荞麦; 其中所述的谷物胚芽为小麦胚芽或者大豆胚芽。 4. The method for preparing lactobacillus fermented cereals or cereal germ extracts according to claim 1, wherein the cereals are barley, barley, or buckwheat; and the cereal germs are wheat germs or soybean germs.
5、 乳酸菌发酵谷物或谷物胚芽提取物的用途, 可以用于制备抗肿瘤的功能性食品。 5. The use of lactic acid bacteria fermented cereals or cereal germ extracts can be used to prepare anti-tumor functional foods.
6、 根据权利要求 5所述的乳酸菌发酵谷物或谷物胚芽提取物的用途, 其特征在于具有抗 肿瘤功能食品的制备方法, 按照下述步骤进行: 将发酵谷物或谷物胚芽提取物以一定的比例 直接加入到发酵乳制品以及其他酸性饮料中, 制成功能性饮料; 也可将其作为食品配料加入
权 利 要 求 书 6. The use of lactic acid bacteria fermented cereals or cereal germ extracts according to claim 5, characterized in that the preparation method of foods with anti-tumor functions is carried out according to the following steps: fermenting cereals or cereal germ extracts in a certain proportion Add directly to fermented dairy products and other acidic beverages to make functional drinks; it can also be added as a food ingredient Claims
WO 2014/206279 PCT/CN2014/080665 面包、 面条、 香肠以及饼干等食品中; 发酵谷物或谷物胚芽提取物也可直接作为食品; 分离 纯化的活性部分可作为功能性食品或进行抗肿瘤药物开发; 将发酵谷物或谷物胚芽提取物加 入到食品中并无特别的重量要求, 加入量以质量比计一般为 1%〜15%, 优选 4%〜10%。
WO 2014/206279 PCT/CN2014/080665 In foods such as bread, noodles, sausages and biscuits; fermented cereals or cereal germ extracts can also be used directly as food; the isolated and purified active parts can be used as functional foods or for the development of anti-tumor drugs; There are no special weight requirements for adding fermented grain or grain germ extract to food. The amount added is generally 1% to 15% in terms of mass ratio, preferably 4% to 10%.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310261606.6A CN103468600B (en) | 2013-06-26 | 2013-06-26 | Lactic acid bacterium used for fermenting cereal and applications thereof |
CN201310264094.9 | 2013-06-26 | ||
CN201310261606.6 | 2013-06-26 | ||
CN201310264094.9A CN103445068B (en) | 2013-06-26 | 2013-06-26 | Preparation method of barley extract fermented by lactobacillus and anti-tumor effect of barley extract fermented by lactobacillus |
CN201310259726.2 | 2013-06-26 | ||
CN201310259726.2A CN103461858B (en) | 2013-06-26 | 2013-06-26 | The preparation method of lactobacillus-fermented Wheat Germ Extracts and antitumor action thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014206279A1 true WO2014206279A1 (en) | 2014-12-31 |
Family
ID=52141065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/080665 WO2014206279A1 (en) | 2013-06-26 | 2014-06-24 | Lactic acid bacteria and preparation method and use of fermented grains or grain germ extracts |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014206279A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109234179A (en) * | 2018-10-29 | 2019-01-18 | 贵州茅台酒股份有限公司 | Yeast isolation culture medium and preparation method thereof in a kind of fermented grain |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1709409A (en) * | 2004-06-18 | 2005-12-21 | 欧德有限公司 | Anti-tumor agent, beverages and foods using the same, and a process for manufacturing the anti-tumor agent |
US20120121612A1 (en) * | 2009-05-20 | 2012-05-17 | United States Government As The Represented By The | Fermented wheat germ proteins (fwgp) for the treatment of cancer |
CN102613518A (en) * | 2012-03-30 | 2012-08-01 | 江苏大学 | Jerusalem artichoke pickle produced by direct-vat-set lactobacillus brevis leavening agent, and process of same |
CN103461858A (en) * | 2013-06-26 | 2013-12-25 | 江苏大学 | Preparation method of lactobacillus fermented wheat germ extract (LFWGE) and anti-tumor effects of lactobacillus fermented wheat germ extract |
-
2014
- 2014-06-24 WO PCT/CN2014/080665 patent/WO2014206279A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1709409A (en) * | 2004-06-18 | 2005-12-21 | 欧德有限公司 | Anti-tumor agent, beverages and foods using the same, and a process for manufacturing the anti-tumor agent |
US20120121612A1 (en) * | 2009-05-20 | 2012-05-17 | United States Government As The Represented By The | Fermented wheat germ proteins (fwgp) for the treatment of cancer |
CN102613518A (en) * | 2012-03-30 | 2012-08-01 | 江苏大学 | Jerusalem artichoke pickle produced by direct-vat-set lactobacillus brevis leavening agent, and process of same |
CN103461858A (en) * | 2013-06-26 | 2013-12-25 | 江苏大学 | Preparation method of lactobacillus fermented wheat germ extract (LFWGE) and anti-tumor effects of lactobacillus fermented wheat germ extract |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109234179A (en) * | 2018-10-29 | 2019-01-18 | 贵州茅台酒股份有限公司 | Yeast isolation culture medium and preparation method thereof in a kind of fermented grain |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106413724B (en) | Lactobacillus rhamnosus RHT-3201 conjugated with polysaccharide polymer binder and uses thereof | |
KR101295444B1 (en) | Novel microorganism for red ginseng fermenting, ferment solution and fermentative red ginseng drink using the same | |
CN110835614B (en) | Bifidobacterium lactis GKK2, composition containing same and application of composition in improving allergic asthma | |
CN103356716A (en) | Fermented composition of multiple probiotics and composite medicinal and edible fungi, and preparation method and application thereof | |
WO2023134203A1 (en) | Application of bacteroides fragilis and zwitterionic capsular polysaccharide thereof in preparation of drug for treating respiratory system tumor | |
CN113913346B (en) | Lactobacillus paracasei JN-1 and application thereof | |
CN109259146A (en) | One plant has effects that inhibit the Lactobacillus rhamnosus of fatty live lesions and its application | |
JP2010047504A (en) | Atopic dermatitis mitigative | |
CN114107121B (en) | Bacillus coagulans and application thereof in treatment of alcoholic liver disease | |
CN103468600B (en) | Lactic acid bacterium used for fermenting cereal and applications thereof | |
KR101379404B1 (en) | Fermentation product of scutellaria baicalensis and antibacterial and immune enhancing composition comprising the same | |
CN103445068A (en) | Preparation method of barley extract fermented by lactobacillus and anti-tumor effect of barley extract fermented by lactobacillus | |
CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
CN110295130A (en) | One plant of Lactobacillus rhamnosus and its application | |
CN103461858B (en) | The preparation method of lactobacillus-fermented Wheat Germ Extracts and antitumor action thereof | |
CN113604410B (en) | Lactobacillus plantarum YT013 and application thereof | |
JP5740613B2 (en) | Disease prevention / improvement agent, endurance improver, anti-fatigue agent, and pharmaceuticals and foods and drinks using them | |
CN114470003B (en) | Application of bacteroides fragilis or zwitterionic capsular polysaccharide thereof in preparing medicines for preventing and treating digestive system tumors | |
KR101965582B1 (en) | Fermented red ginseng concentrate with improved absorption and blood concentration retention time of effective ingredient of red ginseng using fermentation by lactic acid bacteria and the products containing fermented red ginseng concentrate thereof as effective factor | |
KR101396842B1 (en) | Fermentation product of schisandra chinensis and antibacterial and immune enhancing composition comprising the same | |
CN116970539B (en) | Lactobacillus murine complex, composition and application thereof | |
CN114032190A (en) | Lactobacillus reuteri capable of fermenting dendrobium and effectively repairing solar dermatitis by fermentation liquor of dendrobium | |
CN116445356B (en) | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof | |
WO2014206279A1 (en) | Lactic acid bacteria and preparation method and use of fermented grains or grain germ extracts | |
CN103981232A (en) | Preparation method of functional lactobacillus acidophilus peptidoglycan and anti-inflammatory activity use of functional lactobacillus acidophilus peptidoglycan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14818793 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14818793 Country of ref document: EP Kind code of ref document: A1 |